ESC 2026: Tirzepatide 5mg sustains cardiometabolic benefit with weight maintenance - Pharmaceutical Technology

KOLs interviewed by GlobalData consistently recognized tirzepatide's cardiometabolic value as extending well beyond weight loss alone. KOLs interviewed by GlobalData consistently recognized tirzepatide's cardiometabolic value as extending well beyond weight loss alone. A post-hoc analysis of the Phase IIIb SURMOUNT-MAINTAIN trial examined the correlation between cardiometabolic parameters and weight reduction maintenance in tirzepatide treatment when the dose was reduced from the maximum tolerated dose (MTD) to 5 mg. Image credit: [agustin.photo]/Shutterstock.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical…

Source: Pharmaceutical Technology